Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26 wk, suggesting tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, El-Ali, Ali, Roubert, Bernard, El-Beshlawy, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229712/
https://www.ncbi.nlm.nih.gov/pubmed/21668502
http://dx.doi.org/10.1111/j.1600-0609.2011.01662.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229712/
https://www.ncbi.nlm.nih.gov/pubmed/21668502
http://dx.doi.org/10.1111/j.1600-0609.2011.01662.x

Ejemplares similares